Synthaverse

Synthaverse Gross Margin

The Gross Margin of Synthaverse (SVE.WA) as of Nov 22, 2026 is 30.93 %. In the previous year, Gross Margin was 61.67 % — a change of -49.84% (lower).

Gross Margin

30.93 %

YoY

-49.84%

Last updated:

Gross Margin of Synthaverse is 2025 30.93 % . Gross Margin of Synthaverse was 2024 61.67 % . It decreases by -49.84% lower compared to the previous year.

Synthaverse's gross margin stands at 30.9%, down from 55.1% several years earlier.

The Synthaverse Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
50.02 PLN
Jan 1, 2019
54.35 PLN
Jan 1, 2020
51.21 PLN
Jan 1, 2021
55.08 PLN
Jan 1, 2022
56.50 PLN
Jan 1, 2023
60.00 PLN
Jan 1, 2024
61.67 PLN
Jan 1, 2025
30.93 PLN
The Synthaverse Gross Margin history
YEARGross MarginYoY
30.93 %-49.84%
61.67 %+2.77%
60.00 %+6.20%
56.50 %+2.58%
55.08 %+7.55%
51.21 %-5.76%
54.35 %+8.64%
50.02 %+11.89%
44.71 %+22.10%
36.62 %+97.99%
18.49 %-60.71%
47.07 %+5,649.53%
0.82 %-14.28%
0.96 %+27.67%
0.75 %-3.21%
0.77 %+261.84%
0.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

Gross Margin of Synthaverse is 30.93 % in 2025.

Gross Margin of Synthaverse changed from 61.67 % to 30.93 %, representing a -49.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Synthaverse since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Synthaverse with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Synthaverse

All Key Metrics — Synthaverse